

Article

Impact of Lockdown Measures on Health Outcomes of Adults with Type 2 Diabetes Mellitus in Bangladesh

Farhana Akter ¹, Ahsanul Haq ², Brian Godman ^{3,4,5,*}, Kona Chowdhury ⁶, Santosh Kumar ⁷
and Mainul Haque ^{8,*}

¹ Department of Endocrinology, Chittagong Medical College Hospital, Chattogram 4203, Bangladesh

² Infectious Diseases Division, icddr, b, Mohakhali, Dhaka 1212, Bangladesh

³ Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK

⁴ Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0208, South Africa

⁵ Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman 346, United Arab Emirates

⁶ Department of Pediatrics, Gonoshasthaya Somaj Vittik Medical College, Dhaka 1344, Bangladesh

⁷ Department of Periodontology and Implantology, Karnavati School of Dentistry, Karnavati University, Gandhinagar 382422, Gujarat, India

⁸ Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia

* Correspondence: brian.godman@strath.ac.uk (B.G.); runurono@gmail.com (M.H.)

Abstract: COVID-19 lockdown measures appreciably affected patients' lifestyles, negatively impacting on their health. This includes patients with Type 2 Diabetes Mellitus (T2DM). Care of these patients was also negatively impacted due to a priority to treat patients with COVID-19, certainly initially, within hospitals and clinics in Bangladesh, combined with a lack of access to clinics and physicians due to lockdown and other measures. This is a concern in Bangladesh with growing rates of T2DM and subsequent complications. Consequently, we sought to critically analyze the situation among patients with T2DM in Bangladesh during the initial stages of the pandemic to address this information gap and provide future direction. Overall, 731 patients were recruited by a simple random sampling method among patients attending hospitals in Bangladesh, with data collected over 3 timescales: before lockdown, during the pandemic, and after lockdown. Data extracted from patients' notes included current prescribed medicines and key parameters, including blood sugar levels, blood pressure, and comorbidities. In addition, the extent of record keeping. The glycemic status of patients deteriorated during lockdown, and comorbidities as well as complications related to T2DM increased during this period. Overall, a significant proportion of key datasets were not recorded in patients' notes by their physician before and during lockdown. This started to change after lockdown measures eased. In conclusion, lockdown measures critically affected the management of patients with T2DM in Bangladesh, building on previous concerns. Extending internet coverage for telemedicine, introduction of structured guidelines, and appreciably increasing data recording during consultations is of the utmost priority to improve the care of T2DM patients in Bangladesh.

Keywords: Type 2 Diabetes Mellitus; COVID-19; medical records; symptom control; lockdown; Bangladesh



Citation: Akter, F.; Haq, A.; Godman, B.; Chowdhury, K.; Kumar, S.; Haque, M. Impact of Lockdown Measures on Health Outcomes of Adults with Type 2 Diabetes Mellitus in Bangladesh. *Healthcare* **2023**, *11*, 1191. <https://doi.org/10.3390/healthcare11081191>

Academic Editor: Ioannis Ilias

Received: 17 March 2023

Revised: 11 April 2023

Accepted: 18 April 2023

Published: 21 April 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Several public health measures were introduced across various countries to reduce the spread of COVID-19, and its subsequent impact on morbidity and mortality, in the absence of proven effective treatments and vaccines [1–3]. The measures included lockdown and social distancing, wearing of personal protective equipment (PPE), closure of schools and universities, transport restrictions, as well as the introduction of tracing and quarantining measures [3–11]. Bangladesh was no exception, with multiple activities introduced at the

start of the pandemic to slow the spread of the virus [12–14]. There were also major changes in hospitals to reduce or prevent potential transmission from healthcare staff to patients, and vice versa, as well as from patient to patient. This was especially important as there can easily be 5000 patients a day with outpatient appointments in some public hospitals. The changes included reducing the number of clinics or their closure, with physicians seeking to limit personal contact with patients to reduce nosocomial transmission, and similarly for some patients [15,16]. As a result, there was an increase in telemedicine and other approaches to manage patients, especially those with non-communicable diseases (NCDs), during the pandemic, which helped to replace in-person visits [17–20].

Moves to online consultations can be a concern, however, since such changes may lead to social isolation and loss of regular check-ups, potentially negatively impacting on adherence to medicines and necessary lifestyle changes. Alongside this, there are concerns with the affordability, knowledge, and the infrastructure associated with telemedicine, especially among patients in low- and middle-income countries (LMICs) [18–22]. This can be a major issue for patients with diabetes, especially those in LMICs [23].

Diabetes is a priority area since it is one of the most prevalent NCDs globally, and there are severe clinical manifestations if patients are not carefully managed, which can result in increased morbidity, mortality, and costs [24–26]. This includes Bangladesh, where the prevalence of diabetes, including T2DM, has been growing in recent years, and now affects up to 11.8% of the population [27,28]. These growing prevalence rates have also increased mortality, morbidity, and health-related costs in Bangladesh, exacerbated by concerns with managing coronary vascular disease (CVD) in these patients [29–32]. This is especially the case among the elderly in Bangladesh, where it has been estimated that nearly 60% of the elderly have at least one NCD, including diabetes, with nearly one-quarter having multiple comorbidities [33]. The increased prevalence of diabetes is of the greatest concern in urban areas, including Dhaka and Chittagong in Bangladesh [28], with up to ten million patients receiving care for their diabetes across Bangladesh before the first wave of the pandemic [34]. Overall, it is estimated that in Bangladesh, the number of patients with diabetes will increase to 13.7 million by 2045, unless addressed [29]. Of equal concern is that this may be an under-estimate considering the current appreciable under-diagnosis of patients with diabetes in Bangladesh, exacerbated by the recent COVID-19 pandemic and access to clinics [22,33,35].

Similar to other chronic comorbid conditions, managing patients with T2DM during COVID-19 lockdown can be difficult. As a result, potentially, increases in weight with changes in diet and exercise, as well as reducing control over blood sugar levels, can occur, with non-diabetic individuals found to have an increased risk of T2DM due to weight gain because of lockdown measures [36–39]. However, this may not always be the case [38,40–44]. Having said this, various published studies have shown concerns with weight gain, the control of blood sugar levels, and potentially an increase in complications among patients with T2DM during the pandemic, which have been exacerbated by issues of compliance with prescribed medicines [36,45–47]. In addition, people with diabetes have been found to be more susceptible to being infected with COVID-19, especially those with an uncontrolled glycemic status. If the persistence of poor glycemic control increases among individuals with diabetes, more people will become prone to infections, which will lead to an increase in caseloads [23,47].

We believe few studies to date have been undertaken to assess the impact of COVID-19, and associated lockdown measures, on the management of patients with T2DM in Bangladesh and the future implications, although this is changing [48]. This is a concern considering, as mentioned, the increasing rates of T2DM in Bangladesh [29]. Alongside this, there are also concerns with the high rates of patient co-payments, rising prices, and issues of affordability with managing patients with diabetes in Bangladesh, which have been exacerbated by employment concerns during the pandemic through lockdown and other measures [13,27,28,35,49].

Consequently, we sought to address this information gap with the long-term objective to reduce the extent of complications among patients with T2DM, with their associated impact on morbidity and costs, in this and future pandemics. Our initial pilot study among eight patients in Chittagong Medical College showed that there was typically poor control of blood glucose levels of patients with T2DM during the pandemic [50]. However, there was better control of blood pressure, lipids, and albumin levels. There were also concerns with the appreciable extent of missing knowledge gaps in patients' notes, especially during the pandemic. In view of this, the aim here was to undertake a substantial study in this and other hospitals in Bangladesh. As a result, we could provide practical approaches that can be used to improve the management of patients with T2DM in Bangladesh during this and future pandemics. This includes measures to enhance the continuity of care as well as improve the communication with patients, caregivers, and healthcare providers during a pandemic.

2. Materials and Methods

A mixed-methods approach was used. This included a cross-sectional study among patients with T2DM attending the Department of Endocrinology, Chittagong Medical College Hospital, Chittagong, Bangladesh, a tertiary care public hospital, and Chevron Clinical Laboratory and Diagnostic Center, between December 2019, i.e., before the start of the COVID-19 pandemic, and November 2021. When the clinic at Chittagong Hospital is fully functioning, each physician in the outpatient clinics will typically see 120 to 150 patients in a morning session (lasting from 8.00 am until 1.00 pm), with the hospital typically seeing 5000 patients a day. The patient numbers are lower in the Endocrinology clinics, at 40 to 50 patients per session. The patient numbers during a session are also lower in private clinics, including Chevron Clinical Laboratory and Diagnostic Center. Patients typically attend private clinics in the afternoon, contrasting with clinics in public hospitals which usually operate in the morning.

In Bangladesh, both public and private hospitals have not yet entered digitalized data in a preserving system. These research data were obtained from the patients themselves, preserved or maintained in their treatment file, which they retain. The principal researcher had no control over whether a patient appropriately conserved all records, both for prescription and laboratory findings. Consequently, the possibility for missing data increased as the whole process was manually maintained. Moreover, during the COVID-19 pandemic, families were typically disturbed; hence, treatment files were possibly not well-maintained.

These two hospitals, one public and one private, were purposely chosen to provide data for this study, with an earlier study in Chittagong Medical College Hospital documenting high prevalence rates of T2DM among patients attending outpatient clinics in the hospital [31]. In addition, there is a high prevalence of diabetes in Chittagong, Bangladesh [28]. The inclusion of both public and private hospitals in this study reflects the current situation of managing these patients in Bangladesh [51,52].

2.1. Generation of Case Report Forms

A specifically designed case report form (CRF) was used to assess key measures regarding the management of patients with T2DM. This included HbA1c levels, fasting plasma glucose (FPG) and postprandial blood glucose (PPG) levels, blood pressure (BP), lipid levels (HDL, LDL, triglycerides, and total cholesterol), serum creatinine, and urinary albumin, as well as a range of oral and injectable medicines prescribed to control glycemic levels among T2DM patients, including insulins. The extent of any micro- or macro-vascular complications, as well as any other relevant complications or comorbidities, including thyroid disorders, were also captured in the CRF. The final content of the CRF was based on published papers combined with the knowledge of the co-authors, and subsequently tested in a pilot study before full rollout [31,32,50,53,54]. The clinical datasets included in the CRFs, potential targets, and their references are included in Supplementary Table S1.

2.2. Study Design

Retrospective data were taken from patients' notes. Baseline data were taken from before the start of the COVID-19 pandemic and the subsequent initiation of lockdown measures in Bangladesh, as well as during the pandemic in four divided periods, six months apart. The time periods were: December 2019 (Visit 1), June 2020 (Visit 2), December 2020 (Visit 3), June 2021 (Visit 4), and November 2021 (Visit 5). A six-monthly interval was seen as optimal to monitor the changes in key clinical measures [50].

All diabetic patients attending the Endocrinology outpatient department of Chittagong Medical College and at the Chevron Clinical Laboratory and Diagnostic Center that came to consult their physician were potentially recruited into the study. Typically, patients attending public hospitals in Bangladesh are comparatively poorer and less educated compared with those attending private clinics. Educational background is intimately related to patients' awareness of their disease as well as preserving key documents. This is important in Bangladesh, with, as mentioned, patients typically carrying their documents with them rather than residing in any central repository within hospitals.

Exclusion criteria included those patients without any notes as well as pregnant patients.

At the beginning of the pandemic, due to the lockdown measures, patients could not visit hospitals or physician clinics. In addition, many private physician clinics were also closed. Public hospitals remained open during this period; however, they were typically only dealing with patients with COVID-19, and not those with diabetes. As a result, routine follow-up visits for patients with diabetes were dramatically reduced. Alongside this, patients were also afraid of visiting hospitals due to the fear of COVID-19 infection. The situation had eased by the end of 2021, even though the pandemic was not over. However, its virulence was decreasing.

Since the COVID-19 pandemic was ongoing during the study period with the initiation of lockdown measures, including social distancing, patients typically only started visiting clinics again in November 2021 when they were recruited into the study. Once recruited, a retrospective analysis was undertaken of their accompanying documents. This is because, as mentioned, patients typically carry their own notes with them, with no central repository within the hospitals. In addition, detailed questioning of their medication adherence and any problems, alongside routine monitoring of key datasets, during face-to-face contact with physicians, especially in the public sector, is difficult. This especially considering the number of patients with diabetes seen in a morning clinic in public hospitals and the specific areas that need to be discussed to help control blood sugar levels as well as prevent complications.

There were no sample size calculations since the evidence of the impact of lockdown and other measures on the management of patients with T2DM is conflicting [36,37,41–43].

The developed questionnaire included demographic data, comorbidities, medication compliance, and daily habits before and after the lockdown was introduced. This built on the clinical data requirements contained in the CRFs (Supplementary Table S1), building on the pilot study [50].

2.3. Statistical Analysis

Descriptive statistical analyses were performed using categorical variables with numbers and proportions. All statistical analyses were performed using Stata/MP 15.0, and a machine learning technique was used to perform sentimental analysis to evaluate the most common complaints of the studied participants using Python. Sentiment analysis, also known as opinion mining, is a technique in natural language processing that involves using machine learning algorithms to identify and extract subjective information from textual data, e.g., common complaints from patients. Specifically, this technique involves analyzing a given text to determine the emotional tone (diseases) or sentiment. Machine learning is used in sentiment analysis to train algorithms to recognize patterns in language that indicate a particular sentiment. The process usually involves two phases: training and testing. In the training phase, a dataset of labeled text is used to train the algorithm to

recognize specific sentiment patterns. In the testing phase, the algorithm is applied to new, unlabeled text data, and its performance is evaluated based on how well it can correctly identify the sentiment of the text.

To ascertain lipids and cardiometabolic markers in different periods of the COVID-19 pandemic, a univariate regression model was conducted, and figures were prepared using GraphPad Prism 8.3.2. A p -value of <0.05 was considered significant.

No attempt was made to revise the data if patient records were deficient in a number of parameters. This is because we wanted to document the actual situation to provide future guidance, knowing that record keeping, especially during the pandemic, was suboptimal, with both patients and physicians seeking to minimize the time spent in hospital clinics.

2.4. Ethical Approval

Ethical approval was obtained from the Institutional Review Board of Chittagong Medical College, 57, KB Fazlul Kader Road, Police Station: Panchlaish, Post Office: Chittagong 4203, Bangladesh, obtained with Reference No.: CMC/PG/2021/232, Dated: 6 November 2021. Written informed consent was sought from patients before data collection. Consent was entirely voluntary, with no pressure placed on patients to comply.

3. Results

3.1. Patients and Their Demographics

A total of 730 patients were recruited for the study following verbal consent, with Table 1 describing their characteristics. Among the recruited patients, 504 (69.0%) were female and 226 (31.0%) were male, with almost all the patients being married. From the available information, the levels of obesity were higher among female patients (38.6%) versus males (19.7%).

Table 1. Demographic characteristics of the patients.

Variables	Number (% in Brackets)
Age, mean $\pm$ SD	51.2 $\pm$ 11.3
Age, Category	
<30 years	31 (4.20%)
31–50 years	322 (44.1%)
>50 years	377 (51.6%)
Sex	
Male	226 (31.0%)
Female	504 (69.0%)
Marital Status	
Married	728 (99.7%)
Unmarried	2 (0.30%)
Obesity (based on available information of 565 patients)	
Male	27 (19.7%)
Female	165 (38.6%)

3.2. Key Clinical Data

3.2.1. Clinical Characteristics and Treatments

Table 2 discusses the regular follow-up of patients during the study period. This includes details of extensive missing data before and during the early stages of the pandemic. The situation had appreciably changed by Visits 4 and 5.

Table 2. Details of regular follow-up and clinic attendance between December 2019 and November 2021 (n = 730).

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
Regular Follow-Up					
Yes	61 (8.4%)	14 (2.0%)	26 (3.8%)	42 (6.1%)	510 (69.9%)
No	6 (0.80%)	8 (1.2%)	53 (7.7%)	259 (35.5%)	194 (26.6%)
Not recorded	663 (90.8%)	708 (97.0%)	651 (89.2%)	429 (58.8%)	26 (3.6%)

Note: NR = not recorded.

Table 3 documents details of the key clinical features of the patients that were recorded and available in their notes between December 2019 and November 2021, with an appreciable number not recorded until their visit in November 2021.

Table 3. Key clinical findings between December 2019 and November 2021.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
BMI	25.43 ± 11.41	26.25 ± 8.83	29.14 ± 2.04	28.4 ± 4.80	28.1 ± 4.81
NR	721 (98.8%)	706 (96.7%)	678 (92.8%)	445 (61.0%)	128 (17.5%)
Uncontrolled DM					
Yes	41 (5.6%)	11 (1.5%)	24 (3.3%)	44 (6.0%)	293 (40.1%)
No	26 (1.2%)	11 (1.5%)	55 (7.5%)	257 (35.2%)	293 (40.1%)
NR	663 (90.8%)	708 (90.8%)	708 (90.7%)	429 (58.8%)	27 (3.7%)
Blood sugar levels					
FPG, mmol/L	10.0 ± 2.04	10.75 ± 3.37	11.5 ± 4.7	16.07 ± 45.3	20.5 ± 46.0
PPG, mmol/L	19.2 ± 23.5	13.85 ± 4.00	10.0 ± 2.04	12.6 ± 4.85	17.5 ± 8.3
HbA1c, %	7.82 ± 1.52	8.28 ± 2.75	8.62 ± 2.29	8.51 ± 1.85	9.75 ± 1.85
Lipid levels					
TC, mg/dL	208.7 ± 30.16	208.2 ± 16.77	189.6 ± 49.33	172.1 ± 51.7	196.4 ± 45.3
HDL, mg/dL	42.14 ± 2.54	42.40 ± 6.19	40.15 ± 7.36	42.24 ± 10.28	41.9 ± 14.7
LDL, mg/dL	120.4 ± 28.47	121.2 ± 19.58	114.9 ± 42.43	102.0 ± 37.8	113.8 ± 33.22
TG, mg/dL	177.9 ± 49.56	217.6 ± 46.86	205.5 ± 86.43	186.2 ± 61.2	218.5 ± 119.0
Blood pressure and creatinine levels					
SBP, mmHg	128.7 ± 20.10	137.6 ± 22.87	136.3 ± 19.3	134.2 ± 19.3	133.2 ± 20.2
DBP, mm Hg	81.52 ± 8.45	85.0 ± 11.42	81.16 ± 7.24	80.03 ± 6.80	80.4 ± 7.62
Serum creatinine mg/dL	0.86 ± 0.07	0.74 ± 0.09	0.76 ± 0.72	1.01 ± 0.72	1.00 ± 0.61

Note: NR = not recorded; FPG = fasting plasma glucose levels; PPG = post prandial plasma glucose; TC = total cholesterol; HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglyceride; SBP = systolic blood pressure; DBP = diastolic blood pressure.

The lack of recording of patients' details in Tables 2 and 3 reflects the fact that typically there is only limited time for consultations with patients during their clinic visit. This occurs due to high patient volumes, especially in public hospitals, and the need to quickly review each patient's notes at the start of the short consultation.

Both hospitals taking part in the study are referral hospitals and take patients from both rural and urban areas. Consequently, not every clinical detail will be discussed with patients during each consultation. This reflects the current reality among patients with diabetes in Bangladesh, especially in the public system, with the situation worsening as prevalence rates grow. In addition, both physicians and patients felt the need to reduce any contact time during the COVID-19 pandemic, thereby keeping any consultation and

record keeping to a minimum. However, this began to change by Visit 5, which resulted in appreciably greater follow-up of patients and recording of their key clinical details.

Figure 1 depicts differences in key parameters regarding plasma glucose and HbA1c levels, as well as key cardiovascular markers including blood pressure, before, during, and following the easing of lockdown measures. The figures show the mean alongside the standard deviation, and a univariate regression model was used to estimate the p -values. There was a significant increase in FPG ($p = 0.035$), PPG, and HbA1c levels ($p = 0.009$) once COVID-19 restrictions had been eased (Visit 5) compared to pre-pandemic levels or mid-pandemic (Visit 1). There was also an increase in a number of lipid levels from the middle visits to Visit 5, i.e., TC ($p = 0.006$), LDL ($p = 0.005$), and TG ($p = 0.029$). However, there was a decrease in LDL levels following the initiation of lockdown measures; although, there was an increase after this. There were no changes in either systolic or diastolic blood pressure recordings during the pandemic. However, the data for the initial visits must be treated with caution in view of appreciable missing data. This has been exacerbated by the fact that test data can easily be lost when patients are responsible for their own notes, especially in the public system, and physicians do not always record patient details in their notes due to time pressures. This was further exacerbated during the pandemic, with both patients and physicians wanting to keep contact time, as well as time in the hospital, to a minimum.




Figure 1. Key diabetic, lipids, and cardiometabolic markers in different periods of the COVID-19 pandemic. FPG = fasting plasma glucose levels (A); PPG = post prandial plasma glucose (B); HbA1c% (C); TC = total cholesterol (D); HDL = high-density lipoprotein (E); LDL = low-density lipoprotein (F); TG = triglyceride (G); SBP = systolic blood pressure (H); DBP = diastolic blood pressure (I).

Table S2 records details of oral anti-diabetic medicines and insulins prescribed to patients over the past years to help control their blood sugar levels, with Table S3 providing further details of the injectable medicines prescribed, including insulins.

All patients were prescribed oral anti-diabetic medicines to help control their blood glucose levels, which were supplemented by injectable medicines including insulins if needed (Tables S2 and S3). However, this was not always recorded in the patients' notes. Patients do, however, need a prescription from a physician to be able to obtain their oral medicines or insulin from a community pharmacist.

There was typically no discussion with patients regarding their medicine taking, especially when no medicines were recorded. Consequently, some patients may follow the instructions from previous medications and some may reduce the number or doses of medicines they take themselves, especially if they are experiencing side effects and there was no contact with physicians during the pandemic. Some patients may also be dispensed different medicines from community pharmacists on request, and some may just stop taking their medicines all together due to side effects and other parameters.

Table S4 documents the range of medicines prescribed to help control patients' blood pressure, coagulation, and angina, with Table S5 documenting details of the lipid-lowering medicines prescribed and recorded. These medicines are important to help minimize the extent of cardiovascular events arising from T2DM.

3.2.2. Complications and Comorbidities

Tables S6 and S7 provide details of the extent of complications and comorbidities seen among the studied patients, with Table S8 providing additional details.

The principal reasons for hospitalization during the study period included issues of infection and cardiovascular disease, as well as waiting for surgery for the complications associated with diabetes.

Common complaints among the patients, when recorded, were documented via the sentimental approach using machine learning. Most patients had hypertension (HTN), hypothyroidism, obesity, non-alcoholic fatty liver disease (NAFLD), and ischemic heart disease (IHD).

4. Discussion

We believe this is the first study published in Bangladesh that monitors the actual management of patients with diabetes attending two referral centers in a leading city in Bangladesh, before and during the recent COVID-19 pandemic, as well as when lockdown restrictions were eased. This is important as there have been concerns with patient management across countries if there is limited access to treatment centers during the pandemic, and patients with T2DM are not being encouraged to continually improve their lifestyles as well as adhere to their prescribed medicines [22,45,46,55–57]. In addition, the high prevalence of uncontrolled T2DM and hypertension, as well as delays in the diagnosis of cardiovascular diseases among patients with diabetes before and during the pandemic, with its associated lockdown measures [29–32], further exacerbates concerns in this high-priority population [48,50,58,59]. We are aware that the pandemic has also adversely impacted on the diagnosis and management of other NCDs in LMICs [60,61]. This needs to be taken into consideration in future pandemics as a counter-consideration to aggressive lockdown measures [60,61].

There continued to be concerns with the level of control of blood glucose levels during Visits 1 to 5 (Table 3), with key parameters worsening from Visit 3 onwards (Figure 1). However, there was a considerable lack of recording of key details in patients' notes in Visit 1, which carried on with limited patient contact until Visit 5. Consequently, it is difficult to comment on any changes made in the prescribing of both oral medicines and insulin to better control blood sugar levels. Encouragingly, in Visit 5, there was considerably more recording of key clinical parameters, which included the medicines prescribed. However, there is still appreciable room for improvement with a considerable lack of recording of

any insulins prescribed to further improve the management of patients with T2DM in Bangladesh. This is important if patients with T2DM are to be appropriately managed, which is a growing concern in Bangladesh with increasing prevalence rates [27,28,48].

Encouragingly, blood pressure levels and lipid levels (total cholesterol) documented in Table 3 appeared to be within the agreed levels when these were recorded in patients' notes (Table S1). However, a worsening of lipid levels was observed towards the end of the pandemic, where this information was more thoroughly documented. This needs urgent addressing as cardiovascular events are a key complication of patients with diabetes if their diabetes is not properly managed [24]. Table S6 shows limited prevalence rates for both micro- and macro-vascular complications in the studied patients. However, these rates will increase if patients' diabetes remain uncontrolled and their blood pressure and lipid levels do not remain within target levels (Table S1). This will also impact on subsequent infection and hospitalization rates (Table S8). Consequently, these key clinical parameters need improved monitoring in future visits.

Patient comorbidities (Table S7) are as expected for this population. The most common comorbidity was hypothyroidism, with its highest frequency at the last visit, similar to hyperthyroidism but at a lower frequency. Bronchial asthma and COPD were more prevalent from the third visit onwards, especially around the end of the lockdown period. It is difficult to say anything further considering the extent of missing data in patients' notes.

Potential ways forward to improve record keeping among patients with T2DM in Bangladesh include the use of electronic health records or other eHealth approaches. However, this may take time in Bangladesh considering the limited activities to date [62]. Telehealth as well as eHealth approaches, including remote monitoring of blood glucose levels as well as key parameters including blood pressure, can potentially address the multiple challenges experienced during the current and future pandemics. As a result, we can seek to improve the monitoring of patients with T2DM to reduce potential complications and their impact. However, again, this will take time to become established in Bangladesh, especially among patients attending public clinics [62,63]. mHealth approaches can also increase interactions between patients and physicians to enhance their motivation for lifestyle changes and adherence to medicines. This is especially important among patients living in rural areas, where access to specialist clinics can be difficult [64,65], and during lockdown, which severely impacted patients attending clinics in Bangladesh and across LMICs.

These are considerations for the future. In the meantime, there is a need to enhance record keeping among T2DM patients attending ambulatory care clinics in hospitals throughout Bangladesh, building on the improvements recorded in Visit 5 in these two hospitals. There are already ongoing activities in these two hospitals to improve record keeping in patients' notes to be able to improve future patient management, and we will be following this up in future studies. This will complement activities by the government in Bangladesh, which is also planning steps to improve the recording of patient information by supplying logistics support and trained manpower in public hospitals.

We are aware of a number of limitations with our study. Firstly, we only collected data from two hospitals; however, these were carefully selected to cover both public and private hospitals. There were also considerable gaps in patients' records, especially during the pandemic in order to avoid prolonged exposure time between physicians and patients as well as between patients in busy clinics. In addition, patients themselves missed clinic appointments due to the fear of catching COVID-19 and wanted to keep clinic time to a minimum, which subsequently impacted on the extent of information being recorded in their notes. There were also concerns regarding prescriptions and whether these were collected or taken to pharmacies for filling during the pandemic. Finally, patients themselves may have lost their records during the pandemic. This has created considerable bias in the findings. However, despite these concerns, we believe our findings reflect the current reality for patients with T2DM in Bangladesh and do provide guidance on ways to improve the future care of these patients. We will be following up our findings as lockdown

pressures ease and concerns with the management of these patients in Bangladesh persist. This includes potential ways to improve record keeping.

5. Conclusions

In conclusion, patients with T2DM need regular follow-up to achieve glycemic targets as well as prevent delays in the complications associated with poor control of blood sugar levels. This is a concern during the pandemic, alongside the poor documentation in general of the clinical characteristics of patients in Bangladesh. Telemedicine and other approaches can help address concerns with patient contact and follow-up during a pandemic, especially around key areas of lifestyle modifications and adherence to prescribed medicines. However, challenges remain. Governments and other health organizations should collaborate, firstly to fully evaluate the impact of the pandemic on the management of patients with T2DM across sectors considering the identified challenges. Subsequently, this collaboration could help develop robust guidance to manage patients with T2DM during any pandemic, including the follow-up and motivation of patients, as well as ensuring a regular supply of medicines to treat their diabetes and subsequent complications. This is important in Bangladesh considering the rising prevalence rates of T2DM and its impact. Alongside this, data preservation is also critical to improve the management of patients and their outcomes, which includes managing patients to meet the agreed upon target levels. Consequently, governments in LMICs should focus on electronic health records or other eHealth approaches in the future as the prevalence of NCDs continues to rise. It is worth mentioning that the government of Bangladesh has already taken initiatives to better conserve patient data and records in a computerized model, and we will be following this up. We hope that the private hospitals of the country will follow the same path of developing a digitalized data-keeping system to improve patient care. Therefore, we can anticipate that overall, healthcare research and clinical outcomes will be improved.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/healthcare11081191/s1>, Table S1: Key clinical datasets included in the CRFs and potential targets for patients with T2DM. Table S2: Treatments prescribed to manage patients' blood sugar levels. Table S3: Details of injectable anti-diabetic medicines prescribed, including insulins. Table S4: Details of anti-hypertensives, anticoagulants, and GTN prescribed. Table S5: Details of lipid-lowering medicines prescribed. Table S6: Details of micro- and macro-vascular complication rates among the studied patients. Table S7: Comorbidities seen among the studied population. Table S8: Other complications and key events, containing references [66–90].

Author Contributions: Substantial Contributions to the Conception and Design: F.A., A.H., B.G., K.C., S.K. and M.H. Acquisition of Data: F.A., A.H. and K.C. Analysis and Interpretation of Data: F.A., A.H., B.G., K.C., S.K. and M.H. Supervision: F.A., B.G. and M.H. Drafting the Article: F.A., A.H., B.G., K.C., S.K. and M.H. Revising It Critically for Valuable Intellectual Content: F.A., A.H., B.G., K.C., S.K. and M.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Ethical approval was obtained from the Institutional Review Board of Chittagong Medical College, 57, KB Fazlul Kader Road, Police Station: Panchlaish, Post Office: Chittagong 4203, Bangladesh, obtained with Reference No.: CMC/PG/2021/232, Dated: 6 November 2021.

Informed Consent Statement: Informed consent was obtained from patients prior to accessing their details.

Data Availability Statement: Additional data are available upon reasonable request from the corresponding authors.

Acknowledgments: The authors are grateful to Md Omar Faruk and Koushik Barua for their kind cooperation and collaboration in conducting this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ayouni, I.; Maatoug, J.; Dhoub, W.; Zammit, N.; Fredj, S.B.; Ghammam, R.; Ghannem, H. Effective public health measures to mitigate the spread of COVID-19: A systematic review. *BMC Public Health* **2021**, *21*, 1015. [\[CrossRef\]](#) [\[PubMed\]](#)
2. Thai, P.Q.; Rabaa, M.A.; Luong, D.H.; Tan, D.Q.; Quang, T.D.; Quach, H.L.; Hoang Thi, N.A.; Dinh, P.C.; Nghia, N.D.; Tu, T.A.; et al. The First 100 Days of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Control in Vietnam. *Clin. Infect. Dis.* **2021**, *72*, e334–e342. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Talic, S.; Shah, S.; Wild, H.; Gasevic, D.; Maharaj, A.; Ademi, Z.; Li, X.; Xu, W.; Mesa-Eguiagaray, I.; Rostron, J.; et al. Effectiveness of public health measures in reducing the incidence of COVID-19, SARS-CoV-2 transmission, and COVID-19 mortality: Systematic review and meta-analysis. *BMJ* **2021**, *375*, e068302. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Nussbaumer-Streit, B.; Mayr, V.; Dobrescu, A.I.; Chapman, A.; Persad, E.; Klerings, I.; Wagner, G.; Siebert, U.; Christof, C.; Zachariah, C.; et al. Quarantine alone or in combination with other public health measures to control COVID-19: A rapid review. *Cochrane Database Syst. Rev.* **2020**, *9*, Cd013574.
5. Mueed, A.A.R.; Abdullah, M.; Kazmi, T.; Sultan, F.; Khan, A. School closures help reduce the spread of COVID-19: A pre- and post-intervention analysis in Pakistan. *PLOS Glob. Public Health* **2022**, *2*, e0000266. [\[CrossRef\]](#)
6. Verma, B.K.; Verma, M.; Verma, V.K.; Abdullah, R.B.; Nath, D.C.; Khan, H.T.A.; Verma, A.; Vishwakarma, R.K.; Verma, V. Global lockdown: An effective safeguard in responding to the threat of COVID-19. *J. Eval. Clin. Pr.* **2020**, *26*, 1592–1598. [\[CrossRef\]](#)
7. Gium, T.; Lentiro, K.; Geremew, M.; Migora, B.; Shewamare, S.; Shimbire, M.S. Optimal strategies for COVID-19 prevention from global evidence achieved through social distancing, stay at home, travel restriction and lockdown: A systematic review. *Arch. Public Health* **2021**, *79*, 150. [\[CrossRef\]](#)
8. Etando, A.; Amu, A.A.; Haque, M.; Schellack, N.; Kurdi, A.; Alrasheedy, A.A.; Timoney, A.; Mwita, J.C.; Rwegerera, G.M.; Patrick, O.; et al. Challenges and Innovations Brought about by the COVID-19 Pandemic Regarding Medical and Pharmacy Education Especially in Africa and Implications for the Future. *Healthcare* **2021**, *9*, 1722. [\[CrossRef\]](#)
9. Ng, Y.; Li, Z.; Chua, Y.X.; Chaw, W.L.; Zhao, Z.; Er, B.; Pung, R.; Chiew, C.J.; Lye, D.C.; Heng, D.; et al. Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore—2 January–29 February 2020. *MMWR Morb. Mortal. Wkly Rep.* **2020**, *69*, 307–311. [\[CrossRef\]](#)
10. Lotfi, M.; Hamblin, M.R.; Rezaei, N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. *Clin. Chim. Acta* **2020**, *508*, 254–266. [\[CrossRef\]](#)
11. Huang, X.; Shao, X.; Xing, L.; Hu, Y.; Sin, D.D.; Zhang, X. The impact of lockdown timing on COVID-19 transmission across US counties. *EclinicalMedicine* **2021**, *38*, 101035. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Shammi, M.; Bodrud-Doza, M.; Towfiqul Islam, A.R.M.; Rahman, M.M. COVID-19 pandemic, socioeconomic crisis and human stress in resource-limited settings: A case from Bangladesh. *Heliyon* **2020**, *6*, e04063. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Haque, M.; Islam, S.; Iqbal, S.; Urmi, U.L.; Kamal, Z.M.; Rahman, A.; Kamal, M.; Haque, M.; Jahan, I.; Islam, Z.; et al. Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. *Bangladesh J. Med. Sci.* **2020**, *19*, S36–S50. [\[CrossRef\]](#)
14. Chowdhury, K.; Haque, M.; Lutfur, A.B.; Siddiqui, T.H.; Ahmad, R.; Sultana, I.; Sharma, P.; Lugova, H.; Etando, A.; Godman, B. Impact of the COVID-19 pandemic on dental and medical education in Bangladesh: A pilot study and the implications. *Bangladesh J. Med. Sci.* **2022**, *21*, 451–461. [\[CrossRef\]](#)
15. Rubin, R. COVID-19's Crushing Effects on Medical Practices, Some of Which Might Not Survive. *JAMA* **2020**, *324*, 321–323. [\[CrossRef\]](#)
16. Arnetz, B.B.; Goetz, C.; vanSchagen, J.; Baer, W.; Smith, S.; Arnetz, J.E. Patient-reported factors associated with avoidance of in-person care during the COVID-19 pandemic: Results from a national survey. *PLoS ONE* **2022**, *17*, e0272609. [\[CrossRef\]](#)
17. Alexander, G.C.; Tajanlangit, M.; Heyward, J.; Mansour, O.; Qato, D.M.; Stafford, R.S. Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US. *JAMA Netw. Open* **2020**, *3*, e2021476. [\[CrossRef\]](#)
18. Gareev, I.; Gallyametdinov, A.; Beylerli, O.; Valitov, E.; Alyshov, A.; Pavlov, V.; Izmailov, A.; Zhao, S. The opportunities and challenges of telemedicine during COVID-19 pandemic. *Front. Biosci.* **2021**, *13*, 291–298.
19. Khoshrounejad, F.; Hamednia, M.; Mehrjerd, A.; Pichaghsaz, S.; Jamalirad, H.; Sargolzaei, M.; Hoseini, B.; Aalaei, S. Telehealth-Based Services During the COVID-19 Pandemic: A Systematic Review of Features and Challenges. *Front. Public Health* **2021**, *9*, 711762. [\[CrossRef\]](#)
20. Garfan, S.; Alamoodi, A.H.; Zaidan, B.B.; Al-Zobbi, M.; Hamid, R.A.; Alwan, J.K.; Ahmaro, I.Y.Y.; Khalid, E.T.; Jumaah, F.M.; Albahri, O.S.; et al. Telehealth utilization during the COVID-19 pandemic: A systematic review. *Comput. Biol. Med.* **2021**, *138*, 104878. [\[CrossRef\]](#)
21. Sepúlveda-Loyola, W.; Rodríguez-Sánchez, I.; Pérez-Rodríguez, P.; Ganz, F.; Torralba, R.; Oliveira, D.; Rodríguez-Mañas, L. Impact of social isolation due to COVID-19 on health in older people: Mental and physical effects and recommendations. *J. Nutr. Health Aging* **2020**, *24*, 938–947. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Kluge, H.H.P.; Wickramasinghe, K.; Rippin, H.L.; Mendes, R.; Peters, D.H.; Kontsevaya, A.; Breda, J. Prevention and control of non-communicable diseases in the COVID-19 response. *Lancet* **2020**, *395*, 1678–1680. [\[CrossRef\]](#)
23. Gupta, R.; Ghosh, A.; Singh, A.K.; Misra, A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. *Diabetes Metab. Syndr.* **2020**, *14*, 211. [\[CrossRef\]](#)

24. Chan, J.C.N.; Lim, L.L.; Wareham, N.J.; Shaw, J.E.; Orchard, T.J.; Zhang, P.; Lau, E.S.H.; Eliasson, B.; Kong, A.P.S.; Ezzati, M.; et al. The Lancet Commission on diabetes: Using data to transform diabetes care and patient lives. *Lancet* **2021**, *396*, 2019–2082. [CrossRef] [PubMed]
25. Betts, K.A.; Song, J.; Faust, E.; Yang, K.; Du, Y.; Kong, S.X.; Singh, R. Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes. *Am. J. Manag. Care* **2021**, *27* (Suppl. S20), S369–S374.
26. Moucheraud, C.; Lenz, C.; Latkovic, M.; Wirtz, V.J. The costs of diabetes treatment in low- and middle-income countries: A systematic review. *BMJ Glob. Health* **2019**, *4*, e001258. [CrossRef]
27. Streatfield, P.K.A.K.; Iqbal, A.; Jamil, K.; Haider, M.M.; Khan, S. Hypertension and Diabetes in Bangladesh: Findings from the Bangladesh Demographic and Health Survey (BDHS) 2017–2018 and Policy Implications. 2021. Available online: https://www.data4impactproject.org/wp-content/uploads/2021/07/BDHS_NCDPolicy-Brief_WP-21-247_FINAL-2.pdf (accessed on 8 February 2023).
28. Sathi, N.J.; Islam, M.A.; Ahmed, M.S.; Islam, S.M.S. Prevalence, trends and associated factors of hypertension and diabetes mellitus in Bangladesh: Evidence from BHDS 2011 and 2017–2018. *PLoS ONE* **2022**, *17*, e0267243. [CrossRef] [PubMed]
29. Afroz, A.; Alam, K.; Ali, L.; Karim, A.; Alramadan, M.J.; Habib, S.H.; Magliano, D.J.; Billah, B. Type 2 diabetes mellitus in Bangladesh: A prevalence based cost-of-illness study. *BMC Health Serv. Res.* **2019**, *19*, 601. [CrossRef]
30. Afroz, A.; Alam, K.; Hossain, M.N.; Biswas, A.; Ali, L.; Magliano, D.J.; Billah, B. Burden of macro- and micro-vascular complications of type 2 diabetes in Bangladesh. *Diabetes Metab. Syndr.* **2019**, *13*, 1615–1622. [CrossRef]
31. Akter, F.; Alam, A.S.M.; Hasan, M.; Rana, M.; Chowdhury, N.A.; Karim, M.; Mannan, A. The prevalence of uncontrolled Type 2 diabetes mellitus and its associated factors among people within southern part of Bangladesh. *JCMCTA* **2019**, *30*, 92–98.
32. Afroz, A.; Zhang, W.; Wei Loh, A.J.; Jie Lee, D.X.; Billah, B. Macro- and micro-vascular complications and their determinants among people with type 2 diabetes in Bangladesh. *Diabetes Metab. Syndr.* **2019**, *13*, 2939–2946. [CrossRef] [PubMed]
33. Mistry, S.K.; Ali, A.; Yadav, U.N.; Ghimire, S.; Hossain, M.B.; Das Shuvo, S.; Saha, M.; Sarwar, S.; Nirob, M.M.H.; Sekaran, V.C.; et al. Older adults with non-communicable chronic conditions and their health care access amid COVID-19 pandemic in Bangladesh: Findings from a cross-sectional study. *PLoS ONE* **2021**, *16*, e0255534. [CrossRef] [PubMed]
34. Sujan, M.S.H.; Tasnim, R.; Islam, M.S.; Ferdous, M.Z.; Apu, M.A.R.; Musfique, M.M.; Pardhan, S. COVID-19-specific diabetes worries amongst diabetic patients: The role of social support and other co-variates. *Prim. Care Diabetes* **2021**, *15*, 778–785. [CrossRef]
35. Shariful Islam, S.M.; Lechner, A.; Ferrari, U.; Laxy, M.; Seissler, J.; Brown, J.; Niessen, L.W.; Holle, R. Healthcare use and expenditure for diabetes in Bangladesh. *BMJ Glob. Health* **2017**, *2*, e000033. [CrossRef] [PubMed]
36. Ghosal, S.; Arora, B.; Dutta, K.; Ghosh, A.; Sinha, B.; Misra, A. Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: A cohort analysis. *Diabetes Metab. Syndr. Clin. Res. Rev.* **2020**, *14*, 949–952. [CrossRef]
37. Ruiz-Roso, M.B.; Knott-Torcal, C.; Matilla-Escalante, D.C.; Garcimartín, A.; Sampedro-Núñez, M.A.; Dávalos, A.; Marazuela, M. COVID-19 Lockdown and Changes of the Dietary Pattern and Physical Activity Habits in a Cohort of Patients with Type 2 Diabetes Mellitus. *Nutrients* **2020**, *12*, 2327. [CrossRef]
38. Enriquez-Martinez, O.G.; Martins, M.C.T.; Pereira, T.S.S.; Pacheco, S.O.S.; Pacheco, F.J.; Lopez, K.V.; Huancahuire-Vega, S.; Silva, D.A.; Mora-Urda, A.I.; Rodriguez-Vásquez, M.; et al. Diet and Lifestyle Changes During the COVID-19 Pandemic in Ibero-American Countries: Argentina, Brazil, Mexico, Peru, and Spain. *Front. Nutr* **2021**, *8*, 671004. [CrossRef]
39. Rahman, M.E.; Islam, M.S.; Bishwas, M.S.; Moonajilin, M.S.; Gozal, D. Physical inactivity and sedentary behaviors in the Bangladeshi population during the COVID-19 pandemic: An online cross-sectional survey. *Heliyon* **2020**, *6*, e05392. [CrossRef]
40. Nachimuthu, S.; Vijayalakshmi, R.; Sudha, M.; Viswanathan, V. Coping with diabetes during the COVID-19 lockdown in India: Results of an online pilot survey. *Diabetes Metab. Syndr. Clin. Res. Rev.* **2020**, *14*, 579–582. [CrossRef]
41. Verma, M.; Sharma, P.; Chaudhari, A.; Sharma, M.; Kalra, S. Effect of Lockdown on Diabetes Care During the COVID-19 Pandemic: Result of a Telephone-Based Survey Among Patients Attending a Diabetic Clinic in Northern India. *Cureus* **2021**, *13*, e18489. [CrossRef]
42. Sutkowska, E.; Marciniak, D.M.; Sutkowska, K.; Biernat, K.; Mazurek, J.; Kuciel, N. The impact of lockdown caused by the COVID-19 pandemic on glycemic control in patients with diabetes. *Endocrine* **2022**, *76*, 273–281. [CrossRef] [PubMed]
43. Vilafranca Cartagena, M.; Tort-Nasarre, G.; Romeu-Labayen, M.; Vidal-Alaball, J. The experiences of patients with diabetes and strategies for their management during the first COVID-19 lockdown: A qualitative study. *BMC Nurs.* **2022**, *21*, 124. [CrossRef] [PubMed]
44. García Ulloa, A.C.; Tron-Gómez, M.S.; Díaz-Pineda, M.; Hernández-Juárez, D.; Landa-Anell, M.V.; Melgarejo-Hernández, M.A.; Hernández-Jiménez, S.; CAIPaDi Study Group. Maintenance of Self-Care Activities During COVID-19 Lockdown in Patients with Type 2 Diabetes That Received a Comprehensive Care Program Training. *Diabetes Metab. Syndr. Obes.* **2022**, *15*, 2857–2865. [CrossRef] [PubMed]
45. Tewari, A.; Tewari, V.; Tewari, J. Effect of COVID 19 Lockdown on glycemic parameters in people with type 2 diabetes. *J. Fam. Med. Prim. Care* **2021**, *10*, 2529–2532. [CrossRef]
46. Önmez, A.; Gamsızkan, Z.; Özdemir, Ş.; Kesikbaş, E.; Gökosmanoğlu, F.; Torun, S.; Cinemre, H. The effect of COVID-19 lockdown on glycemic control in patients with type 2 diabetes mellitus in Turkey. *Diabetes Metab. Syndr.* **2020**, *14*, 1963–1966. [CrossRef]

47. Ghosal, S.; Sinha, B.; Majumder, M.; Misra, A. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis. *Diabetes Metab. Syndr. Clin. Res. Rev.* **2020**, *14*, 319–323. [\[CrossRef\]](#)
48. Talukder, S.H.; Islam, T.; Salahin, K.F.; Akter, S.; Farhana, F.; Sultana, U.F.; Islam, S.M.S.; Shi, Z.; Hussain, A.; Godman, B.; et al. COVID-19 and Health System Response for Management of Diabetes in Bangladesh: A national qualitative study of patients with diabetes and key healthcare professionals/policy makers. *medRxiv* **2023**, 18.22283405.
49. Jennings, H.M.; Morrison, J.; Akter, K.; Haghparast-Bidgoli, H.; King, C.; Ahmed, N.; Kuddus, A.; Shaha, S.K.; Nahar, T.; Azad, K.; et al. Care-seeking and managing diabetes in rural Bangladesh: A mixed methods study. *BMC Public Health* **2021**, *21*, 1445. [\[CrossRef\]](#)
50. Akter, F.; Haque, M.; Akter, S.; Uddin, G.; Chy, N.; Kameera, F.; Kurdi, A.; Chowdhury, K.; Godman, B. Assessing the management of patients with type 2 diabetes in Bangladesh during pre- and post-COVID-19 era and the implications: A pilot study. *J. Appl. Pharm. Sci.* **2022**, *12*, 88–97. [\[CrossRef\]](#)
51. Haque, M.; Islam, S.; Kamal, Z.M.; Akter, F.; Jahan, I.; Rahim, M.S.A.; Sultana, N.; Alam, A.M.; Murshid, M.E.; Halim-Khan, M.A.; et al. Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications. *Hosp. Pr.* **2021**, *49*, 266–272. [\[CrossRef\]](#)
52. Godman, B.; Haque, M.; Leong, T.; Allocati, E.; Kumar, S.; Islam, S.; Charan, J.; Akter, F.; Kurdi, A.; Vassalo, C.; et al. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. *Front. Public Health* **2021**, *9*, 671961. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Mwita, J.C.; Godman, B.; Esterhuizen, T.M. Statin prescription among patients with type 2 diabetes in Botswana: Findings and implications. *BMC Endocr. Disord.* **2020**, *20*, 36. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Park, P.H.; Pastakia, S.D. Access to Hemoglobin A1c in Rural Africa: A Difficult Reality with Severe Consequences. *J. Diabetes Res.* **2018**, *2018*, 6093595. [\[CrossRef\]](#)
55. Tagoe, E.T.; Nonvignon, J.; van Der Meer, R.; Megiddo, I.; Godman, B. Challenges to the delivery of clinical diabetes services in Ghana created by the COVID-19 pandemic. *J. Health Serv. Res. Policy* **2023**, *28*, 58–65. [\[CrossRef\]](#)
56. Asheq, A.; Ashames, A.; Al-Tabakha, M.; Hassan, N.; Jairoun, A. Medication adherence in type 2 diabetes mellitus patients during COVID-19 pandemic: A cross-sectional study from the United Arab Emirates. *F1000Res* **2021**, *10*, 435. [\[CrossRef\]](#) [\[PubMed\]](#)
57. Shimels, T.; Asrat Kassu, R.; Bogale, G.; Bekele, M.; Getnet, M.; Getachew, A.; Shewamene, Z.; Abraha, M. Magnitude and associated factors of poor medication adherence among diabetic and hypertensive patients visiting public health facilities in Ethiopia during the COVID-19 pandemic. *PLoS One* **2021**, *16*, e0249222. [\[CrossRef\]](#) [\[PubMed\]](#)
58. Abdisa, L.; Alemu, A.; Heluf, H.; Sertsu, A.; Dessie, Y.; Negash, B.; Ayana, G.M.; Letta, S. Factors associated with poor medication adherence during COVID-19 pandemic among hypertensive patients visiting public hospitals in Eastern Ethiopia: A cross-sectional study. *BMJ Open* **2022**, *12*, e064284. [\[CrossRef\]](#)
59. da Luz Pádua Guimarães, M.C.; Coelho, J.C.; Dos Santos, J.; de Oliveira Higa, C.B.; Flórido, C.F.; Lee, R.J.W.; Paes, G.S.; da Silva, G.V.; Drager, L.F.; Pierin, A.M.G. Adherence to antihypertensive treatment during the COVID-19 pandemic: Findings from a cross-sectional study. *Clin. Hypertens.* **2022**, *28*, 35. [\[CrossRef\]](#)
60. Sabetkish, N.; Rahmani, A. The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view. *Health Sci. Rep.* **2021**, *4*, e386. [\[CrossRef\]](#)
61. Prodhan, A.H.M.S.U.; Islam, D.Z.; Khandker, S.S.; Jamiruddin, M.R.; Abdullah, A.; Godman, B.; Opanga, S.; Kumar, S.; Sharma, P.; Adnan, N. Breast Cancer Management in the Era of COVID-19; Key Issues, Contemporary Strategies, and Future Implications. *Breast Cancer Targets Ther.* **2023**, *15*, 51–89. [\[CrossRef\]](#)
62. Rahman, H.; Rubel, M.H.; Sadiá, B.; Sarker, N.E.; Kabir, M.S.; Sreya, A.J.; Monaem, T.; Hasan, R.; Mitun, S.N.; Rahman, S.M.T.; et al. Use of Telemedicine in Bangladesh: Current Status and Future Prospects. *N. Am. Res.* **2022**, *5*, 1–13.
63. Hood, K.K.; Wong, J.J. Telehealth for people with diabetes: Poised for a new approach. *Lancet Diabetes Endocrinol.* **2022**, *10*, 8–10. [\[CrossRef\]](#) [\[PubMed\]](#)
64. Morrison, J.; Akter, K.; Jennings, H.; Ahmed, N.; Kumer Shaha, S.; Kuddus, A.; Nahar, T.; King, C.; Haghparast-Bidgoli, H.; Khan, A.K.A.; et al. Learning from a diabetes mHealth intervention in rural Bangladesh: What worked, what did not and what next? *Glob. Public Health* **2022**, *17*, 1299–1313. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Yasmin, F.; Nahar, N.; Banu, B.; Ali, L.; Sauerborn, R.; Souares, A. The influence of mobile phone-based health reminders on patient adherence to medications and healthy lifestyle recommendations for effective management of diabetes type 2: A randomized control trial in Dhaka, Bangladesh. *BMC Health Serv. Res.* **2020**, *20*, 520. [\[CrossRef\]](#) [\[PubMed\]](#)
66. Health Improvement Scotland. SIGN 154—Pharmacological Management of Glycaemic Control in People with Type 2 Diabetes. 2017. Available online: <https://www.sign.ac.uk/media/1090/sign154.pdf> (accessed on 28 January 2023).
67. Wang, W.; Lee, E.T.; Howard, B.V.; Fabsitz, R.R.; Devereux, R.B.; Welty, T.K. Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: The strong heart study. *Diabetes Care* **2011**, *34*, 363–368. [\[CrossRef\]](#)
68. Kaur, G.; Lakshmi, P.V.M.; Rastogi, A.; Bhansali, A.; Jain, S.; Teerawattananon, Y.; Bano, H.; Prinja, S. Diagnostic accuracy of tests for type 2 diabetes and prediabetes: A systematic review and meta-analysis. *PLoS ONE* **2020**, *15*, e0242415. [\[CrossRef\]](#)
69. Rwegerera, G.M.; Shailemo, D.H.P.; Pina Rivera, Y.; Mokgosi, K.O.; Bale, P.; Oyewo, T.A.; Luis, B.D.; Habte, D.; Godman, B. Metabolic Control and Determinants Among HIV-Infected Type 2 Diabetes Mellitus Patients Attending a Tertiary Clinic in Botswana. *Diabetes Metab. Syndr. Obes.* **2021**, *14*, 85–97. [\[CrossRef\]](#)

70. Zhu, L.; Yang, W.J.; Spence, C.B.; Bhimla, A.; Ma, G.X. Lean Yet Unhealthy: Asian American Adults Had Higher Risks for Metabolic Syndrome than Non-Hispanic White Adults with the Same Body Mass Index: Evidence from NHANES 2011–2016. *Healthcare* **2021**, *9*, 1518. [\[CrossRef\]](#)
71. Mwita, J.C.; Francis, J.M.; Omech, B.; Botsile, E.; Oyewo, A.; Mokgwathi, M.; Molefe-Baikai, O.J.; Godman, B.; Tshikuka, J.G. Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: A cross-sectional study. *BMJ Open* **2019**, *9*, e026807. [\[CrossRef\]](#)
72. Rwegerera, G.M.; Masaka, A.; Pina-Rivera, Y.; Moshomo, T.; Gaenamang, M.; Godman, B.; Oyewo, T.A.; Massele, A.; Habte, D. Determinants of glycemic control among diabetes mellitus patients in a tertiary clinic in Gaborone, Botswana: Findings and implications. *Hosp. Pr.* **2019**, *47*, 34–41. [\[CrossRef\]](#)
73. Rwegerera, G.M.; Molefe-Baikai, O.J.; Masaka, A.; Shimwela, M.; Rivera, Y.P.; Oyewo, T.A.; Godman, B.; Massele, A.; Habte, D. Prevalence of chronic kidney disease using estimated glomerular filtration rate among diabetes patients attending a tertiary clinic in Botswana. *Hosp. Pr.* **2018**, *46*, 214–220. [\[CrossRef\]](#) [\[PubMed\]](#)
74. Perkovic, V.; Agarwal, R.; Fioretto, P.; Hemmelgarn, B.R.; Levin, A.; Thomas, M.C.; Wanner, C.; Kasiske, B.L.; Wheeler, D.C.; Groop, P.H.; et al. Management of patients with diabetes and CKD: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. *Kidney Int.* **2016**, *90*, 1175–1183. [\[CrossRef\]](#) [\[PubMed\]](#)
75. Leon, B.M.; Maddox, T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. *World J. Diabetes* **2015**, *6*, 1246–1258. [\[CrossRef\]](#) [\[PubMed\]](#)
76. Begum, A.; Irfan, S.R.; Hoque, M.R.; Habib, S.H.; Parvin, S.; Malek, R.; Akhter, S.; Sattar, S.; Sarkar, S. Relationship between HbA1c and Lipid Profile Seen in Bangladeshi Type 2 Diabetes Mellitus Patients Attending BIRDEM Hospital: A Cross-Sectional Study. *Mymensingh Med. J. MMJ* **2019**, *28*, 91–95. [\[PubMed\]](#)
77. Jellinger, P.S.; Handelsman, Y.; Rosenblit, P.D.; Bloomgarden, Z.T.; Fonseca, V.A.; Garber, A.J.; Grunberger, G.; Guerin, C.K.; Bell, D.S.H.; Mechanick, J.I.; et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. *Endocr. Pract.* **2017**, *23* (Suppl. S2), 1–87. [\[CrossRef\]](#)
78. Collins, R.; Armitage, J.; Parish, S.; Sleight, P.; Peto, R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. *Lancet* **2003**, *361*, 2005–2016. [\[PubMed\]](#)
79. Norris, K.C.; Smoyer, K.E.; Rolland, C.; Van der Vaart, J.; Grubb, E.B. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: A systematic literature review. *BMC Nephrol.* **2018**, *19*, 36. [\[CrossRef\]](#)
80. Yokoyama, H.; Araki, S.; Honjo, J.; Okizaki, S.; Yamada, D.; Shudo, R.; Shimizu, H.; Sone, H.; Moriya, T.; Haneda, M. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. *Diabetes Care* **2013**, *36*, 3227–3233. [\[CrossRef\]](#)
81. Aziz, K.M. Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring. *Recent Pat. Endocr. Metab. Immune Drug Discov.* **2015**, *9*, 121–133. [\[CrossRef\]](#)
82. Hasanato, R.M. Diagnostic efficacy of random albumin creatinine ratio for detection of micro and macro-albuminuria in type 2 diabetes mellitus. *Saudi Med. J.* **2016**, *37*, 268–273. [\[CrossRef\]](#)
83. Idowu, A.A.; Ajose, A.O.; Adedeji, A.T.; Adegoke, A.O.; Jimoh, K.A. Microalbuminuria, Other Markers of Nephropathy and Biochemical Derangements in Type 2 Diabetes Mellitus: Relationships and Determinants. *Ghana Med. J.* **2017**, *51*, 56–63. [\[PubMed\]](#)
84. Jelinek, H.F.; Osman, W.M.; Khandoker, A.H.; Khalaf, K.; Lee, S.; Almahmeed, W.; Alsafar, H.S. Clinical profiles, comorbidities and complications of type 2 diabetes mellitus in patients from United Arab Emirates. *BMJ Open Diabetes Res. Care* **2017**, *5*, e000427. [\[CrossRef\]](#) [\[PubMed\]](#)
85. Hoque, S.; Muttalib, M.; Islam, M.I.; Happy, T.A. Evaluation of Different HbA1c Levels to Assess the Risk of Peripheral Neuropathy Among Type 2 Diabetic Patients Along with Other Conventional Risk Factors. *Bangladesh Med. Res. Counc. Bull.* **2017**, *42*, 95–103. [\[CrossRef\]](#)
86. Akhter, A.; Fatema, K.; Ahmed, S.F.; Afroz, A.; Ali, L.; Hussain, A. Prevalence and Associated Risk Indicators of Retinopathy in a Rural Bangladeshi Population with and without Diabetes. *Ophthalmic Epidemiol.* **2013**, *20*, 220–227. [\[CrossRef\]](#)
87. Milionis, H.; Ntaios, G.; Papavasileiou, V.; Spengos, K.; Manios, E.; Elisaf, M.; Vemmos, K. Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. *J. Stroke Cereb. Dis* **2017**, *26*, 2769–2777. [\[CrossRef\]](#)
88. Qin, Z.Y.; Yang, X.F.; Lian, C.Y.; Yan, X.J.; Lin, M.S.; Bundhun, P.K.; Lao, Y.Y. Aspirin Versus Clopidogrel Monotherapy for the Secondary Prevention of Recurrent Cerebrovascular Attack Following Previous Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Diabetes* **2020**, *11*, 1091–1101. [\[CrossRef\]](#)
89. Gläser, S.; Krüger, S.; Merkel, M.; Bramlage, P.; Herth, F.J. Chronic obstructive pulmonary disease and diabetes mellitus: A systematic review of the literature. *Respir. Int. Rev. Thorac. Dis.* **2015**, *89*, 253–264. [\[CrossRef\]](#)
90. Zhang, P.; Lopez, R.; Attaway, A.H.; Georas, S.N.; Khatri, S.B.; Abi-Saleh, S.; Zein, J.G. Diabetes Mellitus Is Associated with Worse Outcome in Patients Hospitalized for Asthma. *J. Allergy Clin. Immunol. Pract.* **2021**, *9*, 1562–1569.e1. [\[CrossRef\]](#)

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.